Trial · NCT07891468
huCART19-IL18-CD428z Cells for the Treatment of Patients With HIV With CD19+ Cancers
NCT07891468, Phase 1, Not yet recruiting, University of Pennsylvania
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. huCART19-IL18-CD428z Cells for the Treatment of Patients With HIV With CD19+ Cancers. Trials, record NCT07891468. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07891468
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- huCART19-IL18-CD428z Cells for the Treatment of Patients With HIV With CD19+ Cancers
- NCT number
- NCT07891468
- Status
- Not yet recruiting
- Phases
- Phase 1
- Enrollment
- 6 participants, estimated
- Lead sponsor
- University of Pennsylvania
- Conditions
- Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Richter's Transformation
- Interventions
- huCART19-IL18-CD428z cells
- First posted
- 2026-10-23
- Last updated
- 2026-11-02
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Evaluate the safety of huCART19-IL18-CD428z cells | Up to 15 years post-infusion | Type, frequency, severity, and attribution of AEs/SAEs as assessed by CTCAE V6.0 |
| Primary | Evaluate the safety of huCART19-IL18-CD428z cells | 28 days post-huCART19-IL18-CD428z infusion | Occurrence of treatment-limiting toxicities (TLTs) |
| Secondary | Evaluate manufacturing feasibility | 2 months following enrollment | Occurrence of product release failures; occurrence of dose failures |
| Secondary | Overall Response Rate (ORR) - NHL/CLL/RT participants | Month 3 | Proportion of subjects with CR or PR at Month 3 as compared to baseline |
| Secondary | Overall Response Rate (ORR) - ALL participants | Day 28 | Proportion of subjects with CR/CRi/CRh/CRMRD- at Day 28 as compared to baseline. |
| Secondary | Best Overall Response (BOR) - NHL/CLL/RT participants | Month 3 - end of Primary Follow-Up | Proportion of subjects with a best overall response of CR or PR recorded between Month 3 and the end of Primary Follow-Up, as compared to baseline. |
| Secondary | Best Overall Response (BOR) - ALL participants | Day 28 - Month 6 | Proportion of subjects with a best overall response of CR/CRi/CRh/CRmrd- between Day 28 and Month 6, as compared to baseline. |
| Secondary | Duration of Response (DOR) - NHL/CLL/RT participants | Up to 15 years post-huCART19-IL18-CD428z infusion | Time from the date when the response criteria of CR/PR is first met (at or following Month 3), to the date of disease progression/relapse or death, whichever occurs first. |
| Secondary | Duration of Response (DOR) - ALL participants | Up to 15 years post-huCART19-IL18-CD428z infusion | Time from the date when the response criteria of CR/CRi/CRh/CRmrd- is first met (at or following Day 28), to the date of disease progression/relapse or death, whichever occurs first. |
| Secondary | Progression-free Survival (PFS) - NHL/CLL/RT participants | Up to 15 years post-huCART19-IL18-CD428z infusion | Duration of time from the huCART19-IL18-CD428z infusion to the date of confirmed disease progression or death, whichever occurs first. |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07891468
GET https://conductscience.org/api/trials/v1/NCT07891468/registered